AKT1 and cancer: The most substantial evidence comes from a clinical trial called IPATential150, which examined the combination of ipatasertib (an AKT inhibitor) and abiraterone (an androgen biosynthesis inhibitor) in patients with cancer that lacked PTEN expression.